No Data
Giant Biologic (02367) issued a total of 7.684 million shares on January 21 due to the exercise of stock option plans.
Giant Biologic (02367) announced that on January 21, 2025, a total of 7 shares will be issued due to the exercise of the stock option plan...
An Intrinsic Calculation For Giant Biogene Holding Co., Ltd. (HKG:2367) Suggests It's 49% Undervalued
Hong Kong stocks movement | Juzhi Biological (02367) rose nearly 3% in the morning, with Institutions indicating that injection products will become an important long-term growth engine for the company.
Giant Biologics (02367) rose nearly 3% in the morning, as of the writing, it increased by 2.93%, priced at HKD 54.5, with a transaction value of HKD 69.3484 million.
The highest single transaction price exceeds 0.5 million yuan! The small peak in medical beauty before the festival "arrives as scheduled", and the differentiation of Institutions intensifies further | Fax.
① With the Spring Festival approaching, the medical beauty Industry is experiencing a small surge in Consumer spending, and medium to large medical beauty Institutions have recently seen a significant increase in customer flow. ② Hyaluronic acid, facial rejuvenation injections, and collagen, which have short recovery times and clear effects, remain the "favorites" of Consumers before the holiday. ③ The differentiation among medical beauty Institutions of different sizes is intensifying.
Zhiyin International: Maintaining a "Buy" rating for Juzi Biotechnology with the Target Price raised to HKD 69.19.
CMB International released a research report stating that it raised the Target Price for Giant Biologics (02367) by 4.6%, from HKD 66.15 to HKD 69.19, maintaining a Buy rating. Considering the company has raised its revenue growth guidance for 2024 and exceeded previous expectations, it has raised the expected annual compound revenue growth for 2023-2025 to 43.5%. The report mentions that the GMV growth of KofuMei and KoliGold online in 2024 is impressive. Giant Biologics has raised its 2024 performance guidance, expecting revenue growth of over 50% and a net profit growth of around 40% for the parent company. The firm continues to be bullish on the company's skincare product line.
Citi: Reiterates the "Buy" rating for Juzi Biotechnology (02367) and raises the Target Price to HKD 61.
Citibank expects Zhuzi Bio's revenue to increase by 52% year-on-year in 2024.
Giant Biogene Holding Co., Ltd. (HKG:2367) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap?
